POLBF - Poolbeg Pharma in a very healthy cash position after first full year of operations
(NewsDirect)
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF)CEO Jeremy Skillington speaks to Proactive after publishing finalresults for 2022 that show that the clinical-stage biotech companyfinished its first full year of operations with £16.2mln. Skillingtondescribes it as a "very healthy cash position" and summariseshis main highlights from the year, before looking ahead to what themarket can expect from Poolbeg during the rest of 2023.
PoolbegPharma PLC (AIM:POLB, OTCQB:POLBF) has said it is working towardsits first partnering ‘transaction’ for POLB 001 after a successfulperiod in which it conducted a first human challenge study on its leadasset to assess its potential in severe flu.
On its own, this would be a significantachievement. However, the drug developer has been active in broadeningits pipeline in 2022 – adding POLB 002 for severe respiratory virusinfections and POLB 003 for melioidosis.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.